Nektar Therapeutics Reports First Quarter 2009 Financi...( Accumulated deficit ...)

Date:5/6/2009

Accumulated deficit (1,155,897) (1,124,090) ---------- ---------- Total stockholders' equity 159,274 190,154 ------- ------- Total liabilities and stockholders' equity $505,939 $560,536 ======== ======== (1) The consolidated balance sheet at December 31, 2008 has been derived from the audited financial statements at that date but does not include all of the information and notes required by generally accepted accounting principles in the United States for complete financial statements. Certain 2008 amounts have been reclassified between line items to conform with the 2009 presentation. NEKTAR THERAPEUTICS CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands, except per share information) (unaudited) Three-Months Ended March 31, --------------- 2009 2008 ---- ---- Cash flows used in operating activities: Net loss $(31,807) $(40,705) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 3,615 5,917 Stock-based compensation 2,325 1,084 Other non-cash transactions 115 (112) Changes in assets and liabilities: Decrease (increase) in trad
'/>"/>

SOURCE Nektar Therapeutics Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related biology technology :

1. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
2. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
3. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
4. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
5. Nektar Therapeutics President and CEO Howard Robin to Present at 2007 BIO InvestorForum
6. Nektar Therapeutics to Present at 2007 BMO Capital Markets Focus on Healthcare Conference
7. Nektar Therapeutics President and CEO Howard W. Robin to Present At JPMorgan 26th Annual Healthcare Conference
8. Nektar Appoints Hoyoung Huh, M.D., Ph.D., to Serve on the Companys Board of Directors
9. Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization
10. West Concludes Agreement with Nektar
11. Nektar to Announce Q1 2008 Financial Results on Wednesday, May 7, 2008, After Close of U.S.-Based Financial Markets